PMID- 30171880
OWN - NLM
STAT- MEDLINE
DCOM- 20181015
LR  - 20211204
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 210
DP  - 2018 Oct 1
TI  - Honokiol protects pulmonary microvascular endothelial barrier against 
      lipopolysaccharide-induced ARDS partially via the Sirt3/AMPK signaling axis.
PG  - 86-95
LID - S0024-3205(18)30526-5 [pii]
LID - 10.1016/j.lfs.2018.08.064 [doi]
AB  - AIMS: Acute respiratory distress syndrome (ARDS) is characterized by acute 
      hypoxemia with diffuse alveolar damage and increased pulmonary microvascular 
      permeability. Honokiol (HKL), the principal active ingredient of Chinese herb 
      magnolia officinalis, protected the lung of experimental ARDS models via 
      attenuation of inflammation and oxidative stress. However, whether HKL has 
      protective effects against the dysfunction of pulmonary microvascular endothelial 
      barrier and the potential mechanisms remain unclear. MAIN METHODS: In the present 
      study, we examined the levels of plasma Angiopoietin-2 (Ang-2) in ARDS patients, 
      explored the effects of HKL on the vascular endothelial barrier at the ARDS 
      animal and cell levels. KEY FINDINGS: Our data showed that compared with the 
      healthy controls, circulating Ang-2 level was higher in the patients with ARDS, 
      and were usually supposed to be positively related to the severity of ARDS. 
      Moreover, HKL effectively inhibited lung inflammatory injury and microvascular 
      leakage, and improved ARDS mice survival. HKL also inhibited the expression of 
      Ang-2, ICAM-1 and VCAM-1, and restored the expression of Sirt3, beta-Catenin and 
      VE-Cadherin. Furthermore, HKL improved ECs survival and inhibited the apoptosis 
      of ECs. The inhibition of Ang-2 expression in vitro by HKL is accompanied by the 
      upregulation of Sirt3 and AMPK phosphorylation. SIGNIFICANCE: Our data 
      demonstrated that HKL protected pulmonary microvascular endothelial barrier 
      against LPS-induced ARDS at least in part through activating the Sirt3/AMPK 
      signaling and inhibiting the Ang-2 expression. Thus, our findings show that the 
      activation of Sirt3 signaling is a potential mechanism for the protective effects 
      of HKL on vascular barrier.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Chen, Lan
AU  - Chen L
AD  - Department of Respiratory and Critical Care Medicine, the Second Affiliated 
      Hospital of Chongqing Medical University, Chongqing 400010, China.
FAU - Li, Wen
AU  - Li W
AD  - Department of Respiratory and Critical Care Medicine, the Second Affiliated 
      Hospital of Chongqing Medical University, Chongqing 400010, China.
FAU - Qi, Di
AU  - Qi D
AD  - Department of Respiratory and Critical Care Medicine, the Second Affiliated 
      Hospital of Chongqing Medical University, Chongqing 400010, China.
FAU - Lu, Ling
AU  - Lu L
AD  - Department of Respiratory and Critical Care Medicine, the Second Affiliated 
      Hospital of Chongqing Medical University, Chongqing 400010, China.
FAU - Zhang, Zhengwei
AU  - Zhang Z
AD  - Department of Respiratory and Critical Care Medicine, the Second Affiliated 
      Hospital of Chongqing Medical University, Chongqing 400010, China.
FAU - Wang, Daoxin
AU  - Wang D
AD  - Department of Respiratory and Critical Care Medicine, the Second Affiliated 
      Hospital of Chongqing Medical University, Chongqing 400010, China. Electronic 
      address: wangdaoxin01@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180829
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (ANGPT2 protein, human)
RN  - 0 (Angiopoietin-2)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Lignans)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Sirt3 protein, mouse)
RN  - 11513CCO0N (honokiol)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
RN  - EC 3.5.1.- (Sirtuin 3)
SB  - IM
MH  - AMP-Activated Protein Kinase Kinases
MH  - Angiopoietin-2/metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Biphenyl Compounds/*pharmacology
MH  - Capillary Permeability/*drug effects
MH  - Case-Control Studies
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Endothelium, Vascular/*drug effects/metabolism/pathology
MH  - Enzyme Inhibitors/pharmacology
MH  - Humans
MH  - Lignans/*pharmacology
MH  - Lipopolysaccharides/*toxicity
MH  - Lung/*blood supply
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Protein Kinases/*metabolism
MH  - Respiratory Distress Syndrome/chemically induced/metabolism/pathology/*prevention 
      & control
MH  - Signal Transduction
MH  - Sirtuin 3/*metabolism
OTO - NOTNLM
OT  - ARDS
OT  - Ang-2
OT  - Honokiol
OT  - Pulmonary microvascular endothelial barrier
OT  - Sirt3
EDAT- 2018/09/02 06:00
MHDA- 2018/10/16 06:00
CRDT- 2018/09/02 06:00
PHST- 2018/07/11 00:00 [received]
PHST- 2018/08/27 00:00 [accepted]
PHST- 2018/09/02 06:00 [pubmed]
PHST- 2018/10/16 06:00 [medline]
PHST- 2018/09/02 06:00 [entrez]
AID - S0024-3205(18)30526-5 [pii]
AID - 10.1016/j.lfs.2018.08.064 [doi]
PST - ppublish
SO  - Life Sci. 2018 Oct 1;210:86-95. doi: 10.1016/j.lfs.2018.08.064. Epub 2018 Aug 29.